Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix [clinicaltrials:NCT00064077]

Bio2RDF identifier

NCT00064077

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00064077

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00064077

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

513

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00064077 arm group 525c38f2d78b48bfde6996c767f1d017 [clinicaltrials_resource:NCT00064077/arm-group/525c38f2d78b48bfde6996c767f1d017]

NCT00064077 arm group 8da8309bc4d183e6c8d4eb97f8f09519 [clinicaltrials_resource:NCT00064077/arm-group/8da8309bc4d183e6c8d4eb97f8f09519]

NCT00064077 arm group a5d46a6d80b0d307c94e2b5580eeb62b [clinicaltrials_resource:NCT00064077/arm-group/a5d46a6d80b0d307c94e2b5580eeb62b]

NCT00064077 arm group f42bbe5b8ccc246f1ebb07a843fdab50 [clinicaltrials_resource:NCT00064077/arm-group/f42bbe5b8ccc246f1ebb07a843fdab50]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

This randomized phase I ...... in treating cervical cancer.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Comparison of Four Combination ...... ersistent Cancer of the Cervix

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:58e06c83f67d2f31262212991108054d]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:863ccbea7ba84f81550ae6386d348a31]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:b5fc640b191487e11751ff4a0f3b4235]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:ee11e093b12f1f819ac1030ed21bd1a5]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:fefd8bcf19b3f956969b82c8ddc54423]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:047a931db2fcd14b0d699d142b5f77c4]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:3145b6ea6f6ce74c9f824aaf68f1d56e]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:3477e2aa50a95d2fd08eeff34e782e96]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:962c04b5b35caf62e4714c22a868a928]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:eb3acf2f244ee1eb0baec408a9dadef8]

Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale Baseline [clinicaltrials_resource:fd914d0c7aeb1aade5d5810cc54cb440]

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVES: ...... en annually thereafter.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00064077 [clinicaltrials_resource:371367793e4b0c9ea4ea2d3eab979400]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2003-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Topotecan Hydrochloride [clinicaltrials_resource:481058239109234bf0d9e57a320f7e69]

Cisplatin [clinicaltrials_resource:4cef923a82c9159410c95c182577d87c]

Gemcitabine Hydrochloride [clinicaltrials_resource:6a9994385e863f513d851c2ae218bea2]

Vinorelbine Tartrate [clinicaltrials_resource:a024c6f3539b3979af77cc00d89b8fac]

Quality-of-Life Assessment [clinicaltrials_resource:a238a56933c2e9eb41127ece35eb04d2]

Paclitaxel [clinicaltrials_resource:b1875ca4f9feae023b0da77d98f7fb51]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Vinorelbine [clinicaltrials_resource:160a473a7306febcc326488838e1f57d]

Vinblastine [clinicaltrials_resource:403775ca523bfd23545292b9d1a3de94]

Gemcitabine [clinicaltrials_resource:4d99204da5359df3cebe99857807a801]

Succinylcholine [clinicaltrials_resource:5557dbbb3e844c63bf08fa7d62b3bdda]

Paclitaxel [clinicaltrials_resource:9fab0945b0ae4f7c78a778811b9935ca]

Topotecan [clinicaltrials_resource:a0d83cb90a83e7b4102ec7894178d8dc]

Cisplatin [clinicaltrials_resource:b8c8989cecf98bb7fbbfc2be8c78bee6]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Gynecologic Oncology Group [clinicaltrials_resource:ae9c0f8d700a9cdb2018c9197ec22bf2]

location [clinicaltrials_vocabulary:location]

Gynecologic Oncology Group [clinicaltrials_resource:e6134c14d3f729308d0216cf826a8ee4]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00064077

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

4

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Randomized Phase III Trial O ...... istent Carcinoma of the Cervix

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

GOG-0204

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Bradley Monk [clinicaltrials_resource:50c52a787953444f4526665a261be316]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

NCI-2012-02540

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Gynecologic Oncology Group [clinicaltrials_resource:ae9c0f8d700a9cdb2018c9197ec22bf2]

start date [clinicaltrials_vocabulary:start-date]

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00064077 study design [clinicaltrials_resource:3305aec83b06d5743a8bea9155a4de37]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00064077

verification date [clinicaltrials_vocabulary:verification-date]

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00064077

http://www.w3.org/2001/XMLSchema#string

title

Comparison of Four Combination ...... ersistent Cancer of the Cervix

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Comparison of Four Combination ...... x [clinicaltrials:NCT00064077]

@en